#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The demand for naturally produced astaxanthin is estimated to witness an exponential growth of 25 % ( CAGR ) by 2025 .
3-1	17-20	The	abstract[3]	new[3]	coref	5-23[19_3]
3-2	21-27	demand	abstract[3]	new[3]	_	_
3-3	28-31	for	abstract[3]	new[3]	_	_
3-4	32-41	naturally	abstract[3]|substance[4]	new[3]|new[4]	coref	5-13[0_4]
3-5	42-50	produced	abstract[3]|substance[4]	new[3]|new[4]	_	_
3-6	51-62	astaxanthin	abstract[3]|substance[4]	new[3]|new[4]	_	_
3-7	63-65	is	_	_	_	_
3-8	66-75	estimated	_	_	_	_
3-9	76-78	to	_	_	_	_
3-10	79-86	witness	_	_	_	_
3-11	87-89	an	abstract[5]	new[5]	_	_
3-12	90-101	exponential	abstract[5]	new[5]	_	_
3-13	102-108	growth	abstract[5]	new[5]	_	_
3-14	109-111	of	abstract[5]	new[5]	_	_
3-15	112-114	25	abstract[5]|quantity[6]	new[5]|new[6]	_	_
3-16	115-116	%	abstract[5]|quantity[6]	new[5]|new[6]	_	_
3-17	117-118	(	_	_	_	_
3-18	119-123	CAGR	abstract	new	_	_
3-19	124-125	)	_	_	_	_
3-20	126-128	by	_	_	_	_
3-21	129-133	2025	time	new	_	_
3-22	134-135	.	_	_	_	_

#Text=This fact is in accordance with a worldwide trend : consumers seek for natural products that are produced in an environmentally friendly way .
4-1	136-140	This	abstract[9]	new[9]	_	_
4-2	141-145	fact	abstract[9]	new[9]	_	_
4-3	146-148	is	_	_	_	_
4-4	149-151	in	_	_	_	_
4-5	152-162	accordance	abstract[10]	new[10]	_	_
4-6	163-167	with	abstract[10]	new[10]	_	_
4-7	168-169	a	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-8	170-179	worldwide	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-9	180-185	trend	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-10	186-187	:	_	_	_	_
4-11	188-197	consumers	person	new	_	_
4-12	198-202	seek	_	_	_	_
4-13	203-206	for	_	_	_	_
4-14	207-214	natural	abstract[13]	new[13]	coref	5-26[21_13]
4-15	215-223	products	abstract[13]	new[13]	_	_
4-16	224-228	that	_	_	_	_
4-17	229-232	are	_	_	_	_
4-18	233-241	produced	_	_	_	_
4-19	242-244	in	_	_	_	_
4-20	245-247	an	abstract[14]	new[14]	_	_
4-21	248-263	environmentally	abstract[14]	new[14]	_	_
4-22	264-272	friendly	abstract[14]	new[14]	_	_
4-23	273-276	way	abstract[14]	new[14]	_	_
4-24	277-278	.	_	_	_	_

#Text=Moreover , the feed industry , which is the main purchaser of astaxanthin , is growing as well in order to satisfy the demand for animal-based food products such as meat , fish and eggs .
5-1	279-287	Moreover	_	_	_	_
5-2	288-289	,	_	_	_	_
5-3	290-293	the	abstract[16]	new[16]	_	_
5-4	294-298	feed	substance|abstract[16]	new|new[16]	_	_
5-5	299-307	industry	abstract[16]	new[16]	_	_
5-6	308-309	,	_	_	_	_
5-7	310-315	which	_	_	_	_
5-8	316-318	is	_	_	_	_
5-9	319-322	the	abstract[17]	new[17]	_	_
5-10	323-327	main	abstract[17]	new[17]	_	_
5-11	328-337	purchaser	abstract[17]	new[17]	_	_
5-12	338-340	of	abstract[17]	new[17]	_	_
5-13	341-352	astaxanthin	abstract[17]|substance	new[17]|giv	coref	6-3
5-14	353-354	,	_	_	_	_
5-15	355-357	is	_	_	_	_
5-16	358-365	growing	_	_	_	_
5-17	366-368	as	_	_	_	_
5-18	369-373	well	_	_	_	_
5-19	374-376	in	_	_	_	_
5-20	377-382	order	_	_	_	_
5-21	383-385	to	_	_	_	_
5-22	386-393	satisfy	_	_	_	_
5-23	394-397	the	abstract[19]	giv[19]	coref	6-24[32_19]
5-24	398-404	demand	abstract[19]	giv[19]	_	_
5-25	405-408	for	abstract[19]	giv[19]	_	_
5-26	409-421	animal-based	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-27	422-426	food	abstract[19]|substance|abstract[21]	giv[19]|new|giv[21]	coref	7-6
5-28	427-435	products	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-29	436-440	such	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-30	441-443	as	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-31	444-448	meat	abstract[19]|abstract[21]|substance	giv[19]|giv[21]|new	_	_
5-32	449-450	,	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-33	451-455	fish	abstract[19]|abstract[21]|animal	giv[19]|giv[21]|new	_	_
5-34	456-459	and	abstract[19]|abstract[21]	giv[19]|giv[21]	_	_
5-35	460-464	eggs	abstract[19]|abstract[21]|object	giv[19]|giv[21]|new	_	_
5-36	465-466	.	_	_	_	_

#Text=As the astaxanthin market is dominated by synthetic astaxanthin that is made from petro chemistry , new production capacities are needed to meet the increasing demand for naturally produced astaxanthin .
6-1	467-469	As	_	_	_	_
6-2	470-473	the	abstract[26]	new[26]	_	_
6-3	474-485	astaxanthin	substance|abstract[26]	giv|new[26]	coref	6-8[27_0]
6-4	486-492	market	abstract[26]	new[26]	_	_
6-5	493-495	is	_	_	_	_
6-6	496-505	dominated	_	_	_	_
6-7	506-508	by	_	_	_	_
6-8	509-518	synthetic	substance[27]	giv[27]	coref	6-28[33_27]
6-9	519-530	astaxanthin	substance[27]	giv[27]	_	_
6-10	531-535	that	_	_	_	_
6-11	536-538	is	_	_	_	_
6-12	539-543	made	_	_	_	_
6-13	544-548	from	_	_	_	_
6-14	549-554	petro	organization|substance[29]	new|new[29]	_	_
6-15	555-564	chemistry	substance[29]	new[29]	_	_
6-16	565-566	,	_	_	_	_
6-17	567-570	new	abstract[31]	new[31]	_	_
6-18	571-581	production	abstract|abstract[31]	new|new[31]	coref	7-13[39_0]
6-19	582-592	capacities	abstract[31]	new[31]	_	_
6-20	593-596	are	_	_	_	_
6-21	597-603	needed	_	_	_	_
6-22	604-606	to	_	_	_	_
6-23	607-611	meet	_	_	_	_
6-24	612-615	the	abstract[32]	giv[32]	_	_
6-25	616-626	increasing	abstract[32]	giv[32]	_	_
6-26	627-633	demand	abstract[32]	giv[32]	_	_
6-27	634-637	for	abstract[32]	giv[32]	_	_
6-28	638-647	naturally	abstract[32]|substance[33]	giv[32]|giv[33]	coref	15-23[94_33]
6-29	648-656	produced	abstract[32]|substance[33]	giv[32]|giv[33]	_	_
6-30	657-668	astaxanthin	abstract[32]|substance[33]	giv[32]|giv[33]	_	_
6-31	669-670	.	_	_	_	_

#Text=Fermentations with Corynebacterium glutamicum dominate food and feed biotechnology since decades for the production of amino acids e.g. l-glutamate and l-lysine .
7-1	671-684	Fermentations	substance[34]	new[34]	coref	24-19[153_34]
7-2	685-689	with	substance[34]	new[34]	_	_
7-3	690-705	Corynebacterium	substance[34]|animal	new[34]|new	_	_
7-4	706-716	glutamicum	substance[34]	new[34]	_	_
7-5	717-725	dominate	_	_	_	_
7-6	726-730	food	substance	giv	_	_
7-7	731-734	and	_	_	_	_
7-8	735-739	feed	_	_	_	_
7-9	740-753	biotechnology	abstract	new	_	_
7-10	754-759	since	_	_	_	_
7-11	760-767	decades	time	new	_	_
7-12	768-771	for	_	_	_	_
7-13	772-775	the	abstract[39]	giv[39]	_	_
7-14	776-786	production	abstract[39]	giv[39]	_	_
7-15	787-789	of	abstract[39]	giv[39]	_	_
7-16	790-795	amino	abstract[39]|abstract[40]	giv[39]|new[40]	appos	7-21[0_40]
7-17	796-801	acids	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
7-18	802-806	e.g.	_	_	_	_
7-19	807-818	l-glutamate	_	_	_	_
7-20	819-822	and	_	_	_	_
7-21	823-831	l-lysine	abstract	giv	_	_
7-22	832-833	.	_	_	_	_

#Text=This microorganism naturally synthesizes carotenoids as pigments and yet investigations concerning this output are limited .
8-1	834-838	This	animal[42]	new[42]	_	_
8-2	839-852	microorganism	animal[42]	new[42]	_	_
8-3	853-862	naturally	_	_	_	_
8-4	863-874	synthesizes	_	_	_	_
8-5	875-886	carotenoids	substance	new	coref	12-16[83_0]
8-6	887-889	as	_	_	_	_
8-7	890-898	pigments	_	_	_	_
8-8	899-902	and	_	_	_	_
8-9	903-906	yet	_	_	_	_
8-10	907-921	investigations	_	_	_	_
8-11	922-932	concerning	_	_	_	_
8-12	933-937	this	abstract[44]	new[44]	_	_
8-13	938-944	output	abstract[44]	new[44]	_	_
8-14	945-948	are	_	_	_	_
8-15	949-956	limited	_	_	_	_
8-16	957-958	.	_	_	_	_

#Text=The carotenoid/terpenoid precursors dimethylallyl pyrophosphate ( DMAPP ) and isopentenyl pyrophosphate ( IPP ) are derived from the MEP-pathway in this organism . Carotenoid biosynthesis of the natural C50 carotenoid decaprenoxanthin is based on the accumulation of the C40 intermediate lycopene .
9-1	959-962	The	person[46]	new[46]	appos	9-4[47_46]
9-2	963-983	carotenoid/terpenoid	object|person[46]	new|new[46]	_	_
9-3	984-994	precursors	person[46]	new[46]	_	_
9-4	995-1008	dimethylallyl	person[47]	giv[47]	_	_
9-5	1009-1022	pyrophosphate	person[47]	giv[47]	_	_
9-6	1023-1024	(	_	_	_	_
9-7	1025-1030	DMAPP	abstract	new	_	_
9-8	1031-1032	)	_	_	_	_
9-9	1033-1036	and	_	_	_	_
9-10	1037-1048	isopentenyl	abstract|abstract[50]	new|new[50]	appos|appos	9-13[0_50]|9-13[0_50]
9-11	1049-1062	pyrophosphate	abstract[50]	new[50]	_	_
9-12	1063-1064	(	_	_	_	_
9-13	1065-1068	IPP	abstract	giv	_	_
9-14	1069-1070	)	_	_	_	_
9-15	1071-1074	are	_	_	_	_
9-16	1075-1082	derived	_	_	_	_
9-17	1083-1087	from	_	_	_	_
9-18	1088-1091	the	abstract[52]	new[52]	_	_
9-19	1092-1103	MEP-pathway	abstract[52]	new[52]	_	_
9-20	1104-1106	in	_	_	_	_
9-21	1107-1111	this	animal[53]	new[53]	_	_
9-22	1112-1120	organism	animal[53]	new[53]	_	_
9-23	1121-1122	.	_	_	_	_
9-24	1123-1133	Carotenoid	abstract[54]	new[54]	_	_
9-25	1134-1146	biosynthesis	abstract[54]	new[54]	_	_
9-26	1147-1149	of	abstract[54]	new[54]	_	_
9-27	1150-1153	the	abstract[54]|object[57]	new[54]|new[57]	_	_
9-28	1154-1161	natural	abstract[54]|object[57]	new[54]|new[57]	_	_
9-29	1162-1165	C50	abstract[54]|time|object[57]	new[54]|new|new[57]	_	_
9-30	1166-1176	carotenoid	abstract[54]|object|object[57]	new[54]|new|new[57]	coref	10-9
9-31	1177-1193	decaprenoxanthin	abstract[54]|object[57]	new[54]|new[57]	_	_
9-32	1194-1196	is	_	_	_	_
9-33	1197-1202	based	_	_	_	_
9-34	1203-1205	on	_	_	_	_
9-35	1206-1209	the	event[58]	new[58]	_	_
9-36	1210-1222	accumulation	event[58]	new[58]	_	_
9-37	1223-1225	of	event[58]	new[58]	_	_
9-38	1226-1229	the	event[58]|substance[60]	new[58]|new[60]	_	_
9-39	1230-1233	C40	event[58]|abstract|substance[60]	new[58]|new|new[60]	coref	15-17[92_0]
9-40	1234-1246	intermediate	event[58]|substance[60]	new[58]|new[60]	_	_
9-41	1247-1255	lycopene	event[58]|substance[60]	new[58]|new[60]	_	_
9-42	1256-1257	.	_	_	_	_

#Text=The genome of C. glutamicum contains a major carotenoid operon and the regulatory mechanism involving a MarR-type transcriptional regulator CrtR was identified .
10-1	1258-1261	The	object[61]	new[61]	_	_
10-2	1262-1268	genome	object[61]	new[61]	_	_
10-3	1269-1271	of	object[61]	new[61]	_	_
10-4	1272-1274	C.	object[61]|person[62]	new[61]|new[62]	coref	15-8[0_62]
10-5	1275-1285	glutamicum	object[61]|person[62]	new[61]|new[62]	_	_
10-6	1286-1294	contains	_	_	_	_
10-7	1295-1296	a	abstract[64]	new[64]	_	_
10-8	1297-1302	major	abstract[64]	new[64]	_	_
10-9	1303-1313	carotenoid	object|abstract[64]	giv|new[64]	coref	11-15
10-10	1314-1320	operon	abstract[64]	new[64]	_	_
10-11	1321-1324	and	_	_	_	_
10-12	1325-1328	the	abstract[65]	new[65]	_	_
10-13	1329-1339	regulatory	abstract[65]	new[65]	_	_
10-14	1340-1349	mechanism	abstract[65]	new[65]	_	_
10-15	1350-1359	involving	_	_	_	_
10-16	1360-1361	a	substance[67]	new[67]	_	_
10-17	1362-1371	MarR-type	abstract|substance[67]	new|new[67]	_	_
10-18	1372-1387	transcriptional	substance[67]	new[67]	_	_
10-19	1388-1397	regulator	substance[67]	new[67]	_	_
10-20	1398-1402	CrtR	abstract	new	coref	11-29[79_0]
10-21	1403-1406	was	_	_	_	_
10-22	1407-1417	identified	_	_	_	_
10-23	1418-1419	.	_	_	_	_

#Text=Interestingly , this regulation is working in a metabolite dependent manner in which the carotenoid precursor molecule geranylgeranyl pyrophosphate ( GGPP ) is acting as an effector of the repressor CrtR .
11-1	1420-1433	Interestingly	_	_	_	_
11-2	1434-1435	,	_	_	_	_
11-3	1436-1440	this	abstract[69]	new[69]	_	_
11-4	1441-1451	regulation	abstract[69]	new[69]	_	_
11-5	1452-1454	is	_	_	_	_
11-6	1455-1462	working	_	_	_	_
11-7	1463-1465	in	_	_	_	_
11-8	1466-1467	a	abstract[70]	new[70]	_	_
11-9	1468-1478	metabolite	abstract[70]	new[70]	_	_
11-10	1479-1488	dependent	abstract[71]	new[71]	_	_
11-11	1489-1495	manner	abstract[71]	new[71]	_	_
11-12	1496-1498	in	_	_	_	_
11-13	1499-1504	which	_	_	_	_
11-14	1505-1508	the	person[76]	new[76]	coref	19-8[0_76]
11-15	1509-1519	carotenoid	object|person[73]|person[76]	giv|new[73]|new[76]	coref|coref	19-15|19-15
11-16	1520-1529	precursor	person[73]|person[76]	new[73]|new[76]	_	_
11-17	1530-1538	molecule	abstract|person[76]	new|new[76]	_	_
11-18	1539-1553	geranylgeranyl	abstract|person[76]	new|new[76]	coref	19-7
11-19	1554-1567	pyrophosphate	person[76]	new[76]	_	_
11-20	1568-1569	(	_	_	_	_
11-21	1570-1574	GGPP	substance	new	_	_
11-22	1575-1576	)	_	_	_	_
11-23	1577-1579	is	_	_	_	_
11-24	1580-1586	acting	_	_	_	_
11-25	1587-1589	as	_	_	_	_
11-26	1590-1592	an	_	_	_	_
11-27	1593-1601	effector	_	_	_	_
11-28	1602-1604	of	_	_	_	_
11-29	1605-1608	the	abstract[79]	giv[79]	_	_
11-30	1609-1618	repressor	object|abstract[79]	new|giv[79]	_	_
11-31	1619-1623	CrtR	abstract[79]	giv[79]	_	_
11-32	1624-1625	.	_	_	_	_

#Text=Thus , as the genetic background was analyzed in more detail , the production of industrially relevant carotenoids of the C40 family was conducted over the last years (
12-1	1626-1630	Thus	_	_	_	_
12-2	1631-1632	,	_	_	_	_
12-3	1633-1635	as	_	_	_	_
12-4	1636-1639	the	abstract[80]	new[80]	_	_
12-5	1640-1647	genetic	abstract[80]	new[80]	_	_
12-6	1648-1658	background	abstract[80]	new[80]	_	_
12-7	1659-1662	was	_	_	_	_
12-8	1663-1671	analyzed	_	_	_	_
12-9	1672-1674	in	_	_	_	_
12-10	1675-1679	more	abstract[81]	new[81]	_	_
12-11	1680-1686	detail	abstract[81]	new[81]	_	_
12-12	1687-1688	,	_	_	_	_
12-13	1689-1692	the	abstract[82]	new[82]	_	_
12-14	1693-1703	production	abstract[82]	new[82]	_	_
12-15	1704-1706	of	abstract[82]	new[82]	_	_
12-16	1707-1719	industrially	abstract[82]|substance[83]	new[82]|giv[83]	coref	15-20[93_83]
12-17	1720-1728	relevant	abstract[82]|substance[83]	new[82]|giv[83]	_	_
12-18	1729-1740	carotenoids	abstract[82]|substance[83]	new[82]|giv[83]	_	_
12-19	1741-1743	of	abstract[82]|substance[83]	new[82]|giv[83]	_	_
12-20	1744-1747	the	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-21	1748-1751	C40	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-22	1752-1758	family	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-23	1759-1762	was	_	_	_	_
12-24	1763-1772	conducted	_	_	_	_
12-25	1773-1777	over	_	_	_	_
12-26	1778-1781	the	time[85]	new[85]	_	_
12-27	1782-1786	last	time[85]	new[85]	_	_
12-28	1787-1792	years	time[85]	new[85]	_	_
12-29	1793-1794	(	_	_	_	_

#Text=Figure 1
13-1	1795-1801	Figure	object[86]	new[86]	_	_
13-2	1802-1803	1	object[86]	new[86]	_	_

#Text=) .
14-1	1804-1805	)	_	_	_	_
14-2	1806-1807	.	_	_	_	_

#Text=Indeed , metabolic engineering studies showed that C. glutamicum is a suitable host for production of various C40 and C50 carotenoids with astaxanthin as prominant example .
15-1	1808-1814	Indeed	_	_	_	_
15-2	1815-1816	,	_	_	_	_
15-3	1817-1826	metabolic	abstract[88]	new[88]	_	_
15-4	1827-1838	engineering	abstract|abstract[88]	new|new[88]	coref	25-7
15-5	1839-1846	studies	abstract[88]	new[88]	_	_
15-6	1847-1853	showed	_	_	_	_
15-7	1854-1858	that	_	_	_	_
15-8	1859-1861	C.	person	giv	coref	23-16
15-9	1862-1872	glutamicum	_	_	_	_
15-10	1873-1875	is	_	_	_	_
15-11	1876-1877	a	person[90]	new[90]	_	_
15-12	1878-1886	suitable	person[90]	new[90]	_	_
15-13	1887-1891	host	person[90]	new[90]	_	_
15-14	1892-1895	for	person[90]	new[90]	_	_
15-15	1896-1906	production	person[90]|abstract[91]	new[90]|new[91]	coref	16-14[99_91]
15-16	1907-1909	of	person[90]|abstract[91]	new[90]|new[91]	_	_
15-17	1910-1917	various	person[90]|abstract[91]|abstract[92]	new[90]|new[91]|giv[92]	_	_
15-18	1918-1921	C40	person[90]|abstract[91]|abstract[92]	new[90]|new[91]|giv[92]	_	_
15-19	1922-1925	and	person[90]|abstract[91]	new[90]|new[91]	_	_
15-20	1926-1929	C50	person[90]|abstract[91]|substance[93]	new[90]|new[91]|giv[93]	_	_
15-21	1930-1941	carotenoids	person[90]|abstract[91]|substance[93]	new[90]|new[91]|giv[93]	_	_
15-22	1942-1946	with	person[90]|abstract[91]|substance[93]	new[90]|new[91]|giv[93]	_	_
15-23	1947-1958	astaxanthin	person[90]|abstract[91]|substance[93]|substance[94]	new[90]|new[91]|giv[93]|giv[94]	coref	18-18[0_94]
15-24	1959-1961	as	person[90]|abstract[91]|substance[93]|substance[94]	new[90]|new[91]|giv[93]|giv[94]	_	_
15-25	1962-1971	prominant	person[90]|abstract[91]|substance[93]|substance[94]	new[90]|new[91]|giv[93]|giv[94]	_	_
15-26	1972-1979	example	person[90]|abstract[91]|substance[93]|substance[94]	new[90]|new[91]|giv[93]|giv[94]	_	_
15-27	1980-1981	.	_	_	_	_

#Text=The previously published strain ASTA1 possesses a good volumetric productivity , but for industrial scale production further improvement is needed in order to meet economically feasible production titers .
16-1	1982-1985	The	abstract[95]	new[95]	_	_
16-2	1986-1996	previously	abstract[95]	new[95]	_	_
16-3	1997-2006	published	abstract[95]	new[95]	_	_
16-4	2007-2013	strain	abstract[95]	new[95]	_	_
16-5	2014-2019	ASTA1	abstract	new	_	_
16-6	2020-2029	possesses	_	_	_	_
16-7	2030-2031	a	abstract[97]	new[97]	_	_
16-8	2032-2036	good	abstract[97]	new[97]	_	_
16-9	2037-2047	volumetric	abstract[97]	new[97]	_	_
16-10	2048-2060	productivity	abstract[97]	new[97]	_	_
16-11	2061-2062	,	_	_	_	_
16-12	2063-2066	but	_	_	_	_
16-13	2067-2070	for	_	_	_	_
16-14	2071-2081	industrial	abstract[99]	giv[99]	coref	16-27[0_99]
16-15	2082-2087	scale	abstract|abstract[99]	new|giv[99]	_	_
16-16	2088-2098	production	abstract[99]	giv[99]	_	_
16-17	2099-2106	further	abstract[100]	new[100]	_	_
16-18	2107-2118	improvement	abstract[100]	new[100]	_	_
16-19	2119-2121	is	_	_	_	_
16-20	2122-2128	needed	_	_	_	_
16-21	2129-2131	in	_	_	_	_
16-22	2132-2137	order	_	_	_	_
16-23	2138-2140	to	_	_	_	_
16-24	2141-2145	meet	_	_	_	_
16-25	2146-2158	economically	abstract[102]	new[102]	_	_
16-26	2159-2167	feasible	abstract[102]	new[102]	_	_
16-27	2168-2178	production	abstract|abstract[102]	giv|new[102]	coref	18-18[120_0]
16-28	2179-2185	titers	abstract[102]	new[102]	_	_
16-29	2186-2187	.	_	_	_	_

#Text=The construction of fusion proteins and the application of membrane anchors was shown to be an efficient strategy to increase membrane integrity and protein stability .
17-1	2188-2191	The	event[103]	new[103]	_	_
17-2	2192-2204	construction	event[103]	new[103]	_	_
17-3	2205-2207	of	event[103]	new[103]	_	_
17-4	2208-2214	fusion	event[103]|object[104]	new[103]|new[104]	coref	25-15[159_104]
17-5	2215-2223	proteins	event[103]|object[104]	new[103]|new[104]	_	_
17-6	2224-2227	and	event[103]	new[103]	_	_
17-7	2228-2231	the	event[103]|event[105]	new[103]|new[105]	ana	18-1[0_105]
17-8	2232-2243	application	event[103]|event[105]	new[103]|new[105]	_	_
17-9	2244-2246	of	event[103]|event[105]	new[103]|new[105]	_	_
17-10	2247-2255	membrane	event[103]|event[105]|object|object[107]	new[103]|new[105]|new|new[107]	coref|coref	17-21|17-21
17-11	2256-2263	anchors	event[103]|event[105]|object[107]	new[103]|new[105]|new[107]	_	_
17-12	2264-2267	was	_	_	_	_
17-13	2268-2273	shown	_	_	_	_
17-14	2274-2276	to	_	_	_	_
17-15	2277-2279	be	_	_	_	_
17-16	2280-2282	an	abstract[108]	new[108]	coref	21-5[140_108]
17-17	2283-2292	efficient	abstract[108]	new[108]	_	_
17-18	2293-2301	strategy	abstract[108]	new[108]	_	_
17-19	2302-2304	to	_	_	_	_
17-20	2305-2313	increase	_	_	_	_
17-21	2314-2322	membrane	object|abstract[110]	giv|new[110]	_	_
17-22	2323-2332	integrity	abstract[110]	new[110]	_	_
17-23	2333-2336	and	_	_	_	_
17-24	2337-2344	protein	substance|abstract[112]	new|new[112]	coref|coref	18-11[118_0]|18-11[118_0]
17-25	2345-2354	stability	abstract[112]	new[112]	_	_
17-26	2355-2356	.	_	_	_	_

#Text=It was shown that linkage of CrtW and CrtZ with the GlpF protein from E. coli increased astaxanthin production by approximately 2-fold .
18-1	2357-2359	It	event	giv	_	_
18-2	2360-2363	was	_	_	_	_
18-3	2364-2369	shown	_	_	_	_
18-4	2370-2374	that	abstract[114]	new[114]	_	_
18-5	2375-2382	linkage	abstract[114]	new[114]	_	_
18-6	2383-2385	of	abstract[114]	new[114]	_	_
18-7	2386-2390	CrtW	abstract[114]|substance	new[114]|new	_	_
18-8	2391-2394	and	abstract[114]	new[114]	_	_
18-9	2395-2399	CrtZ	abstract[114]|substance	new[114]|new	_	_
18-10	2400-2404	with	_	_	_	_
18-11	2405-2408	the	substance[118]	giv[118]	coref	21-7[0_118]
18-12	2409-2413	GlpF	object|substance[118]	new|giv[118]	_	_
18-13	2414-2421	protein	substance[118]	giv[118]	_	_
18-14	2422-2426	from	substance[118]	giv[118]	_	_
18-15	2427-2429	E.	substance[118]	giv[118]	_	_
18-16	2430-2434	coli	substance[118]	giv[118]	_	_
18-17	2435-2444	increased	_	_	_	_
18-18	2445-2456	astaxanthin	substance|abstract[120]	giv|giv[120]	coref|coref|coref|coref	19-15[128_120]|20-14|19-15[128_120]|20-14
18-19	2457-2467	production	abstract[120]	giv[120]	_	_
18-20	2468-2470	by	_	_	_	_
18-21	2471-2484	approximately	_	_	_	_
18-22	2485-2491	2-fold	_	_	_	_
18-23	2492-2493	.	_	_	_	_

#Text=Moreover , the fusion of a geranylgeranyl pyrophosphate synthase with a phytoene synthase improved carotenoid production in plant cells .
19-1	2494-2502	Moreover	event[121]	new[121]	ana	20-3[0_121]
19-2	2503-2504	,	event[121]	new[121]	_	_
19-3	2505-2508	the	event[121]	new[121]	_	_
19-4	2509-2515	fusion	event[121]	new[121]	_	_
19-5	2516-2518	of	event[121]	new[121]	_	_
19-6	2519-2520	a	event[121]|substance[124]	new[121]|new[124]	_	_
19-7	2521-2535	geranylgeranyl	event[121]|abstract|substance[124]	new[121]|giv|new[124]	_	_
19-8	2536-2549	pyrophosphate	event[121]|person|substance[124]	new[121]|giv|new[124]	_	_
19-9	2550-2558	synthase	event[121]|substance[124]	new[121]|new[124]	_	_
19-10	2559-2563	with	event[121]|substance[124]	new[121]|new[124]	_	_
19-11	2564-2565	a	event[121]|substance[124]|substance[126]	new[121]|new[124]|new[126]	_	_
19-12	2566-2574	phytoene	event[121]|substance[124]|abstract|substance[126]	new[121]|new[124]|new|new[126]	_	_
19-13	2575-2583	synthase	event[121]|substance[124]|substance[126]	new[121]|new[124]|new[126]	_	_
19-14	2584-2592	improved	event[121]|substance[124]	new[121]|new[124]	_	_
19-15	2593-2603	carotenoid	event[121]|substance[124]|object|abstract[128]	new[121]|new[124]|giv|giv[128]	coref|coref|coref|coref	20-11|20-14[136_128]|20-11|20-14[136_128]
19-16	2604-2614	production	event[121]|substance[124]|abstract[128]	new[121]|new[124]|giv[128]	_	_
19-17	2615-2617	in	event[121]|substance[124]|abstract[128]	new[121]|new[124]|giv[128]	_	_
19-18	2618-2623	plant	event[121]|substance[124]|abstract[128]|object|object[130]	new[121]|new[124]|giv[128]|new|new[130]	_	_
19-19	2624-2629	cells	event[121]|substance[124]|abstract[128]|object[130]	new[121]|new[124]|giv[128]|new[130]	_	_
19-20	2630-2631	.	_	_	_	_

#Text=Recently , it was shown that fusion of the terminal carotenoid enzymes increased astaxanthin production in E. coli .
20-1	2632-2640	Recently	_	_	_	_
20-2	2641-2642	,	_	_	_	_
20-3	2643-2645	it	event	giv	_	_
20-4	2646-2649	was	_	_	_	_
20-5	2650-2655	shown	_	_	_	_
20-6	2656-2660	that	_	_	_	_
20-7	2661-2667	fusion	event[132]	new[132]	coref	21-6[0_132]
20-8	2668-2670	of	event[132]	new[132]	_	_
20-9	2671-2674	the	event[132]|substance[134]	new[132]|new[134]	_	_
20-10	2675-2683	terminal	event[132]|substance[134]	new[132]|new[134]	_	_
20-11	2684-2694	carotenoid	event[132]|abstract|substance[134]	new[132]|giv|new[134]	_	_
20-12	2695-2702	enzymes	event[132]|substance[134]	new[132]|new[134]	_	_
20-13	2703-2712	increased	_	_	_	_
20-14	2713-2724	astaxanthin	substance|abstract[136]	giv|giv[136]	coref|coref|coref|coref	23-9|23-5[143_136]|23-9|23-5[143_136]
20-15	2725-2735	production	abstract[136]	giv[136]	_	_
20-16	2736-2738	in	_	_	_	_
20-17	2739-2741	E.	_	_	_	_
20-18	2742-2746	coli	_	_	_	_
20-19	2747-2748	.	_	_	_	_

#Text=In this study , a fusion protein strategy was conducted (
21-1	2749-2751	In	_	_	_	_
21-2	2752-2756	this	event[137]	new[137]	_	_
21-3	2757-2762	study	event[137]	new[137]	_	_
21-4	2763-2764	,	_	_	_	_
21-5	2765-2766	a	abstract[140]	giv[140]	_	_
21-6	2767-2773	fusion	event|abstract[140]	giv|giv[140]	coref	25-15
21-7	2774-2781	protein	substance|abstract[140]	giv|giv[140]	_	_
21-8	2782-2790	strategy	abstract[140]	giv[140]	_	_
21-9	2791-2794	was	_	_	_	_
21-10	2795-2804	conducted	_	_	_	_
21-11	2805-2806	(	_	_	_	_

#Text=Figure 2
22-1	2807-2813	Figure	abstract[141]	new[141]	_	_
22-2	2814-2815	2	abstract[141]	new[141]	_	_

#Text=) that resulted in an approximately five-fold improved astaxanthin production under high glucose concentration in C. glutamicum .
23-1	2816-2817	)	_	_	_	_
23-2	2818-2822	that	_	_	_	_
23-3	2823-2831	resulted	_	_	_	_
23-4	2832-2834	in	_	_	_	_
23-5	2835-2837	an	abstract[143]	giv[143]	coref	24-16[152_143]
23-6	2838-2851	approximately	abstract[143]	giv[143]	_	_
23-7	2852-2861	five-fold	abstract[143]	giv[143]	_	_
23-8	2862-2870	improved	abstract[143]	giv[143]	_	_
23-9	2871-2882	astaxanthin	substance|abstract[143]	giv|giv[143]	coref	24-16
23-10	2883-2893	production	abstract[143]	giv[143]	_	_
23-11	2894-2899	under	_	_	_	_
23-12	2900-2904	high	abstract[145]	new[145]	_	_
23-13	2905-2912	glucose	substance|abstract[145]	new|new[145]	coref	24-10
23-14	2913-2926	concentration	abstract[145]	new[145]	_	_
23-15	2927-2929	in	abstract[145]	new[145]	_	_
23-16	2930-2932	C.	abstract[145]|person	new[145]|giv	_	_
23-17	2933-2943	glutamicum	abstract[145]	new[145]	_	_
23-18	2944-2945	.	_	_	_	_

#Text=Moreover , it turned out that the co-utilization of glucose and potassium acetate significantly improved astaxanthin production in small-scale fermentations .
24-1	2946-2954	Moreover	_	_	_	_
24-2	2955-2956	,	_	_	_	_
24-3	2957-2959	it	_	_	_	_
24-4	2960-2966	turned	_	_	_	_
24-5	2967-2970	out	_	_	_	_
24-6	2971-2975	that	_	_	_	_
24-7	2976-2979	the	abstract[147]	new[147]	_	_
24-8	2980-2994	co-utilization	abstract[147]	new[147]	_	_
24-9	2995-2997	of	abstract[147]	new[147]	_	_
24-10	2998-3005	glucose	abstract[147]|substance	new[147]|giv	_	_
24-11	3006-3009	and	abstract[147]	new[147]	_	_
24-12	3010-3019	potassium	abstract[147]|event|substance[150]	new[147]|new|new[150]	_	_
24-13	3020-3027	acetate	abstract[147]|substance[150]	new[147]|new[150]	_	_
24-14	3028-3041	significantly	_	_	_	_
24-15	3042-3050	improved	_	_	_	_
24-16	3051-3062	astaxanthin	substance|abstract[152]	giv|giv[152]	_	_
24-17	3063-3073	production	abstract[152]	giv[152]	_	_
24-18	3074-3076	in	abstract[152]	giv[152]	_	_
24-19	3077-3088	small-scale	abstract[152]|substance[153]	giv[152]|giv[153]	_	_
24-20	3089-3102	fermentations	abstract[152]|substance[153]	giv[152]|giv[153]	_	_
24-21	3103-3104	.	_	_	_	_

#Text=Thus , not only classical metabolic engineering strategies , but also the construction of fusion proteins and the optimization of cultivation media are powerful strategies to exploit the potential of valuable compound formation .
25-1	3105-3109	Thus	_	_	_	_
25-2	3110-3111	,	_	_	_	_
25-3	3112-3115	not	_	_	_	_
25-4	3116-3120	only	abstract[156]	new[156]	_	_
25-5	3121-3130	classical	abstract[156]	new[156]	_	_
25-6	3131-3140	metabolic	person|abstract[156]	new|new[156]	_	_
25-7	3141-3152	engineering	abstract|abstract[156]	giv|new[156]	_	_
25-8	3153-3163	strategies	abstract[156]	new[156]	_	_
25-9	3164-3165	,	_	_	_	_
25-10	3166-3169	but	_	_	_	_
25-11	3170-3174	also	_	_	_	_
25-12	3175-3178	the	abstract[157]	new[157]	coref	25-24[163_157]
25-13	3179-3191	construction	abstract[157]	new[157]	_	_
25-14	3192-3194	of	abstract[157]	new[157]	_	_
25-15	3195-3201	fusion	abstract[157]|event|substance[159]	new[157]|giv|giv[159]	_	_
25-16	3202-3210	proteins	abstract[157]|substance[159]	new[157]|giv[159]	_	_
25-17	3211-3214	and	abstract[157]	new[157]	_	_
25-18	3215-3218	the	abstract[157]|event[160]	new[157]|new[160]	_	_
25-19	3219-3231	optimization	abstract[157]|event[160]	new[157]|new[160]	_	_
25-20	3232-3234	of	abstract[157]|event[160]	new[157]|new[160]	_	_
25-21	3235-3246	cultivation	abstract[157]|event[160]|plant|abstract[162]	new[157]|new[160]|new|new[162]	_	_
25-22	3247-3252	media	abstract[157]|event[160]|abstract[162]	new[157]|new[160]|new[162]	_	_
25-23	3253-3256	are	_	_	_	_
25-24	3257-3265	powerful	abstract[163]	giv[163]	_	_
25-25	3266-3276	strategies	abstract[163]	giv[163]	_	_
25-26	3277-3279	to	_	_	_	_
25-27	3280-3287	exploit	_	_	_	_
25-28	3288-3291	the	abstract[164]	new[164]	_	_
25-29	3292-3301	potential	abstract[164]	new[164]	_	_
25-30	3302-3304	of	abstract[164]	new[164]	_	_
25-31	3305-3313	valuable	abstract[164]|abstract[166]	new[164]|new[166]	_	_
25-32	3314-3322	compound	abstract[164]|place|abstract[166]	new[164]|new|new[166]	_	_
25-33	3323-3332	formation	abstract[164]|abstract[166]	new[164]|new[166]	_	_
25-34	3333-3334	.	_	_	_	_
